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Abstract: The inflammatory response during aller-
gic airway inflammation involves the recruitment of
multiple leukocyte populations, including neutro-
phils, monocytes, lymphocytes, and eosinophils. All of
these populations likely contribute to the pathology
observed during repeated episodes of allergic airway
inflammation. We have examined the role of a human
neutrophil-specific chemokine (C-x-C), ENA-78 , in a
model of allergic airway responses and identified mu-
rine mast cells as a cellular source of an ENA-78-like
molecule. Within this allergic airway model, neutrophil
infiltration into the airway occurs within 4–8 h post-
allergen challenge, persists within the airway until 24
h, and resolves by 48 h post-challenge. Neutrophil
influx precedes the eosinophil infiltration, which peaks
in the airway at 48 h post-allergen challenge. In this
study the production of ENA-78 from challenged lungs
demonstrated a significant increase in the allergen-,
but not vehicle-, challenged lungs. In vivo neutraliza-
tion of ENA-78 by passive immunization demonstrated
a significant decrease in peak neutrophil infiltration at
8 h, with no effect on the eosinophil infiltration at 48 h
post-challenge. Because ENA-78 has been shown to be
chemotactic for neutrophils and given the involvement
of mast cell degranulation in allergic responses, we
examined mast cells for the presence of ENA-78.
Cultured mast cells spontaneously released ENA-78,
but on activation with IgE 1 antigen, NG-L-arginine
methyl ester or compound 48/80 produced signifi-
cantly increased levels of ENA-78. Supernatants from
sonicated MC-9 mast cells induced an overwhelming
influx of neutrophils into the BAL by 4 h post-
intratracheal injection into mice, suggesting that the
mast cell is a significant sourceof neutrophil chemotac-
tic factors. Mast cell supernatant-mediated neutrophil
infiltration was substantially decreased by preincuba-
tion of the supernatant with antibodies specific for
ENA-78. These data indicate a major neutrophil che-
motactic protein produced by mast cells during aller-
gic responses may be mast cell-derived ENA-78.
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INTRODUCTION
Allergic airway inflammation can have long-term detrimental
effects on an individual and may be induced by mechanisms
contributed by multiple leukocyte populations that infiltrate
during allergen-specific responses. The inflammation induced
during allergic airway inflammation is mediated by the coordi-
nation of several immune specific activational events. The first
leukocyte that appears to enter a site of allergic inflammation is
the neutrophil. The initial induction of IgE-mediated mast cell
degranulation, up-regulation of adhesion molecules, and the
production of inflammatory and chemotactic cytokines leading
to the infiltration of specific leukocyte subsets is orchestrated
in a sequential manner [1–3]. The activation and degranulation
of local mast cell populations is an immediate response in the
airway mediated both by antigen-specific, surface-bound IgE
and by cytokine-induced activational pathways. The relevance
of neutrophils to airway hyperreactivity and subsequent late-
phase reactions and airway damage in atopic asthma has
traditionally been a controversial topic [4]. However, results
collected over recent years have provided data that suggest that
neutrophils, at the very least, have a role in inducing airway
damage leading to lung dysfunction [5–8]. The recruitment of
neutrophils to the airway during allergic responses has been
well documented. Neutrophils are a source of several inflamma-
tory mediators as well as destructive proteases capable of
damaging surrounding tissue in the lungs [9]. Therefore, the
investigation into the recruitment of neutrophils into the airway
during allergic inflammation may be crucial to fully understand
the pathology and related airway responses.
Leukocyte recruitment during inflammation has been shown
to be mediated by nonspecific activators, such as leukotriene B4
(LTB4), platelet-activating factor (PAF), C5a, etc., however,
specific leukocyte populations can be recruited via inflamma-
tion-induced chemokines [10, 11]. Chemokines have been
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divided into two separate families based on their activity and
amino acid homology [11]. The C-x-C family of chemokines,
which includes interleukin-8 (IL-8), ENA-78, GRO a, b, g, as
well as several others, is primarily chemotactic for neutrophils.
The C-C family of chemokines, including monocyte chemoat-
tractant protein (MCP)-1, -2, -3, -4, -5, macrophage inflamma-
tory protein (MIP)-1a/b, eotaxin, RANTES, as well as several
other newer members, are chemotactic for lymphocytes, mono-
cytes, eosinophils, and/or basophils. Chemokines are generated
by a number of tissue resident cells, including endothelial
cells, smooth muscle cells, fibroblasts, epithelial cells, and
mast cells. The identification and regulation of these chemo-
kines during diseases may lead to development of novel
therapeutic interventions designed to interrupt specific phases
of inflammatory responses.
In this study we have utilized an established model of
allergic airway inflammation to examine the presence, activa-
tion, and specific sources of neutrophil chemotactic proteins
during allergic airway responses. The results from this study
indicate that an ENA-78-like protein, a C-x-C chemokine,
plays a major role in allergic neutrophil infiltration. Further-
more, it appears that a significant early source of ENA-78 may
be mast cells activated during the allergen specific response.
MATERIALS AND METHODS
Animals
Female CBA/J mice purchased from Jackson Laboratories (Bar Harbor, ME)
were maintained under standard pathogen-free conditions.
Egg isolation and soluble egg antigen (SEA)
protein preparation
SEA were prepared from acutely Schistosoma mansoni-infected mice as
previously described [12]. Briefly, eggs were isolated from livers of infected
mice after a 3-day incubation and ground on ice to release the soluble antigens
from the egg. The preparation was then spun in an ultracentrifuge at 100,000 g
for 2 h and the supernatant collected. The antigens in the supernatant are
primarily glycoproteins that have been characterized as inducing a TH2 type
granulomatous response in schistosomiasis [13, 14].
Sensitization and induction of the airway
response
To induce a TH2 type response [13, 14] the following procedure was established
in normal CBA/J mice [15]. Briefly, the mice were immunized with 5000
isolated S. mansoni eggs intraperitoneally at days 0 and 7 of the protocol. On
day 14 the mice were given an intranasal challenge of 10 µg of SEA in 10 µL of
phosphate-buffered saline (PBS) to localize the response to the airway. This
initial intranasal challenge with antigen induced little cellular infiltrate into the
lungs of the mice on histological examination. Mice were then rechallenged 6
days later by intratracheal administration of 10 µg of SEA in 25 µL of sterile
PBS or with PBS alone (vehicle). The magnitude of infiltration in both the
vehicle control and SEA-challenged mice was examined histologically. Only
the SEA-challenged mice displayed a significant inflammatory response that
included neutrophil and eosinophil infiltration, as previously described [15].
Quantification and differentiation of leukocyte
populations in bronchoalveolar lavage (BAL)
and lungs
Mice immunized and challenged with SEA or saline vehicle were subjected to a
1-mL BAL with PBS containing 50 mM EDTA at various time points
post-challenge. The cells were then counted, dispersed using a cytospin, and
differentially stained with Wright-Giemsa stain. The cell types (mononuclear
phagocytes, lymphocytes, neutrophils, and eosinophils) were expressed as a
percentage based on 200 total cells counted/sample.
Lung homogenates
Isolated whole-lung tissue was homogenated on ice using a tissue-tearer
(Biospec Products, Racine, WI) for 30 s in 1 mL of PBS containing 0.05%
Triton X-100. Previous results indicate that there was no interference in
enzyme-linked immunosorbent assay (ELISA) measurements with this buffer.
The resulting supernatant was isolated after a high-speed spin (10,000 g) and
subsequent filtration through a 1.2-µm syringe filter (Gelman Sciences, Ann
Arbor, MI). The resultant supernatants were immediately frozen at 270°C until
tested in the ENA-78 ELISA.
MC-9 mast cell line
The MC-9 mast cell line (ATCC no. CRL 8306) is an established long-term,
nontransformed, IL-3-dependent cell line that was derived from fetal liver and
represents a mast cell phenotype. MC-9 mast cells are maintained in
Dulbecco’s modified Eagle’s medium supplemented with 1 mM L-Glu, 10 mM
N-2-hydroxyethylpiperazine-N8-2-ethanesulfonic acid (HEPES), antibiotics,
and 10% fetal calf serum combined with 10% concanavalin A (Con A)-
stimulated rat splenocyte supernatants. MC9 cells were added to six-well tissue
culture plates at a density of 1.0 3 105 cells/well before each experiment. To
duplicate wells containing MC-9 mast cells, one of the following compounds or
combinations of compounds (all obtained from Sigma Chemical Co., St. Louis,
MO) were added: 48/80 (1 µg/mL), L-NAME (1 mM), D-NAME (1 mM),
L-NAME 1 48/80, or D-NAME 1 48/80. Control samples were left untreated.
Compound 48/80 is a potent nonspecific activator of mast cells. Previous
studies have shown that mast cells degranulate after the inhibition of
endogenous nitric oxide production by L-NAME treatment [16]. D-NAME is the
structural enantiomer of L-NAME and has no inhibitory effect on nitric oxide
synthesis [17]. Cell-free supernatants were removed from the culture plates at 2
and 24 h after the start of culture, and assayed for ENA-78 (see below).
ENA-78 ELISA
ENA-78 was quantitated by ELISA using a modification of a double-ligand
method as previously described [18]. The antisera used for these assays were
specific for human ENA-78 but cross-react with a murine molecule that is not
MIP-2, KC, GCP-2, or any other C-x-C chemokine that we have examined.
Therefore we have referred to this molecule as ENA-78. Briefly, flat-bottomed
96-well microtiter plates (Nunc Immuno-Plate I 96-F) were coated with 50
µL/well of rabbit anti-human ENA-78 polyclonal antibody for 16 h at 4°C and
then washed with PBS, pH 7.5, 0.05% Tween-20 (wash buffer). Nonspecific
binding sites were blocked with 2% BSA in PBS and incubated for 90 min at
37°C. Plates were rinsed four times with wash buffer and diluted (1:2 and 1:10)
cell-free supernatants in duplicate were added, followed by incubation for 1 h at
37°C. Plates were washed four times, followed by the addition of 50 µL/well
biotinylated rabbit anti-ENA-78 antibody (3.5 ng/µL in PBS, pH 7.5, 0.05%
Tween-20, and 2% fetal calf serum), and plates incubated for 30 min at 37°C.
Plates were washed four times, streptavidin-peroxidase conjugate (Bio-Rad
Laboratories, Richmond, CA) added, and the plates incubated for 30 min at
37°C. Plates were again washed four times and chromogen substrate (Bio-Rad)
added. The plates were then incubated at room temperature to the desired
extinction, and the reaction terminated with 50 µL/well of 3 M H2SO4 solution.
Plates were read at 490 nm in an ELISA reader. Standards were 0.5 log
dilutions of recombinant ENA-78 from 10 pg/mL to 100 ng/mL. This ELISA
method consistently detected ENA-78 concentrations above 50 pg/mL. The
ENA-78 antibody ELISA did not cross-react with mIL-3, mIL-1a, mTNF,
mMIP-2, mKC, mMIP-1a, IL-6, mJE, mMIP-1b, mIP-10, mGCP-2, hMCP-1,
hIL-8, hGCP-2, hRANTES, hMIP-1a, hTNF, and hMIP-1b.
Mast cell lysates and airway inflammation
To ascertain the ability of mast cells to induce an inflammatory response,
cell-free freeze/thaw lysates of the MC-9 mast cell line (1 3 107 cells/mL) were
injected intratracheally. Four hours after the injected supernatant 1 mL BAL
was harvested from the mice and examined by differential staining for leukocyte
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populations. In separate studies, anti-ENA-78 (1:20 dilution; 106 titer) or
control antibody was used in the supernatant and preincubated for 30 min
before the intratracheal injection.
Statistics
Statistical significance was determined by analysis of variance and significance
was determined with P values , 0.05.
RESULTS
Correlation of ENA-78 production and neutrophil
accumulation in allergen-challenged mice
The accumulation of neutrophils and eosinophils in the air-
space during the allergic response is expressed in Figure 1.
Neutrophil infiltration in BAL fluid samples began between 1
and 4 h, peaked at 8 h, plateaued at 24 h, and dropped to
background levels by 48 h post-allergen challenge. In contrast,
eosinophil accumulation began at 24 h, peaked at 48 h, and
subsequently dropped at later time points. The production of
neutrophil specific chemokines during allergic airway inflam-
mation may be critical for the recruitment of neutrophils
leading to lung damage. To determine the production of
ENA-78, whole lung homogenates were made from the lungs of
mice at various times after allergen challenge, 1, 4, 8, 24, and
48 h. The debris-free supernatants were assayed using a
specific ELISA for ENA-78 (Fig. 2). The production of
ENA-78 in whole lung homogenates demonstrated a significant
increase in ENA-78 as early as 1 h post-allergen challenge,
peaking by 4 h, and plateuing at 8 and 24 h post challenge. By 48 h, ENA-78 levels had returned to control background levels.
The preceding expression of ENA-78 protein in the lung
homogenates correlated with the accumulation of neutrophils
(r2 5 0.79), but not eosinophils during the allergic response
(r2 , 0.1).
Neutralization of ENA-78 decreases neutrophil
infiltration during allergen challenge
The role of ENA-78 was determined by pretreating (1 h) allergic
animals with specific neutralizing anti-ENA-78 or control
antibody before allergen re-challenge. One-milliliter BAL fluid
samples were harvested from the treated animals at 8 h post
allergen challenge. The results in Figure 3 demonstrate a
significant reduction in neutrophil accumulation in the BAL at
8 h post challenge, the time of peak neutrophil influx.
Compared with control antibody-treated animals the neutro-
philic response in the anti-ENA-78-treated animals was re-
duced by 40–50% at 8 h post treatment, the peak time of
response. In contrast, when animals were treated with an
anti-MIP-2 antibody (another neutrophil-specific C-X-C chemo-
kine) no decrease in neutrophil accumulation was observed.
Furthermore, when eosinophil accumulation was examined
within this model, there was no reduction in the anti-ENA-78-
treated animals at 48 h, the time of peak eosinophil accumula-
tion within the airway (data not shown).
Role of mast cell-derived ENA-78
in allergic inflammation
Classical studies have previously described the production and
release of neutrophil chemotactic factors from activated and
Fig. 1. Accumulation of granulocytes after allergen challenge. Sensitized
mice were challenged with SEA and 1 mL BAL was harvested at various time
points, cytospun, differentially stained, and counted. Vehicle-challenged
animals had 10.5 6 0.5% neutrophils and no eosinophils at 8 and 48 h
post-challenge, respectively. Results represent mean 6 SE of at least four
mice/time point. *Significant increases over vehicle-challenged animals, P ,
0.05.
Fig. 2. ENA-78 production in whole lung homogenates during allergic airway
inflammation. Whole lungs from specific time points after allergen challenge
were homogenated in PBS containing 0.1% Triton X-100 and anti-proteases.
The cell-free supernatants were assayed using an ENA-78 specific ELISA.
Data represent mean 6 SE from six individual mice. *Significant increases over
vehicle-challenged animals, P , 0.05.
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degranulated mast cell populations [3]. To examine the poten-
tial of mast cells producing ENA-78 during our allergic
response, allergic mice were pretreated (1 h before allergen
challenge) with 20 mg/kg of cromolyn sodium. Use of cromolyn
sodium significantly reduced the ENA-78 production (P ,
0.05) at 4 h post-challenge by .45% compared with control-
treated animals (data not shown). Using a mature MC-9
nontransformed mast cell line, the presence and role of ENA-78
was evaluated in mast cells. Supernatants from unstimulated
and stimulated MC-9 mast cells were assayed for the presence
of ENA-78 protein using a specific ELISA (Figs. 4 and 5).
Inhibition of NO has previously been shown to cause degranula-
tion of mast cell populations [16]. The spontaneous release of
1.6 6 0.44 ng/mL of ENA-78 was observed in cultures of
untreated or D-NAME-treated MC-9 mast cells after 2 h, and
these levels were increased by threefold after 24 h. In contrast,
L-NAME treatment stimulated the release of 7.3 6 0.21 ng/mL
of ENA-78 after 2 h. Only a minor increase above this
concentration was observed at the 24-h timepoint in the
L-NAME-treated MC-9 cultures (Fig. 4). Approximately 10
ng/mL of ENA-78 was released over a 24-h period after
degranulation of MC-9 mast cells with compound 48/80 in the
absence (7.4 6 2.7 ng/mL) or presence (12.6 6 1.6 ng/mL) of
D-NAME (Fig. 5). However, levels of ENA-78 reached 35.3 6
0.32 ng/mL when MC-9 mast cells were activated with com-
pound 48/80 and L-NAME over a similar culture period (Fig. 5).
In separate studies, bone marrow-derived mast cells (1 3
105/mL) were activated by IgE 1 antigen (DNP) and released
significant amounts of ENA-78 compared to controls (1.36 6
0.22 vs. 0.243 6 0.081 ng/mL, respectively). Taken together,
these results indicate that mast cells have the ability to release
Fig. 3. Neutralization of ENA-78 specifically attenuates neutrophil accumula-
tion in the airways at 8 h post allergen challenge. One-half milliliter of control
or anti-ENA-78 specific serum was injected intraperitoneally into mice 1 h
before allergen challenge. One milliliter BAL was harvested from each mouse
at 8 h post-challenge. Results represent mean 6 SE of at least six individual
mice in each group. *Significant increases over control ab-treated animals, P ,
0.05.
Fig. 4. Release of ENA-78 from MC-9 mast cells in the absence or presence of
NG-nitro-D-arginine methylester (D-NAME) or NG-nitro-L-arginine methyl ester
(L-NAME) for 2 or 24 h. MC-9 cells (1.0 3 105 cells/well) were left untreated or
cultured in the presence of 1 mM D-NAME or L-NAME. Cell-free supernatants
were removed at 2 or 24 h of culture and ENA-78 levels were measured using
ELISA (see Materials and Methods). Results are mean 6 SEM of duplicate wells
from three separate experiments. *Significant increase compared to untreated
or D-NAME-treated values, P , 0.05.
Fig. 5. Compound 48/80-stimulated release of ENA-78 from MC-9 mast cells
in the absence or presence of NG-nitro-D-arginine methyl ester (D-NAME) or
NG-nitro-L-arginine methyl ester (L-NAME) for 24 h. MC-9 cells (1.0 3 105
cells/well) were stimulated with compound 48/80 (1 µg/mL) in the absence or
presence of 1 mM D-NAME or L-NAME. Cell-free supernatants were removed
after 24 h of culture, and ENA-78 levels were measured using ELISA (see
Materials and Methods). Results are mean 6 SEM of duplicate wells from three
separate experiments. *P , 0.05 compared to untreated or D-NAME treated
values.
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ENA-78 spontaneously, and produce ENA-78 on activation and
degranulation.
To examine the neutrophil chemotactic activity of the mast
cells, freeze-thaw lysates were prepared from the MC-9 mast
cell line (1 3 107/mL in PBS). These mast cell lysates
contained ,10 ng/mL of ENA-78. To determine the effect on
neutrophil recruitment in vivo, the lysates were intratracheally
injected into the airways of normal mice. After 4 h post-
challenge, a 1-mL BAL was harvested from the treated mice
and assayed for leukocyte recruitment. The results in Figure 6
indicate that .80% of leukocytes found in the airspace (via
BAL fluid analysis) were neutrophils. When the mast cell
lysates were preincubated with either a control or anti-ENA-78
purified antibody, only the anti-ENA-78-treated supernatant
significantly inhibited the neutrophil infiltration into the air-
way. Preincubation of the supernatant with anti-MIP-2 had no
effect on the neutrophil recruitment to the airway (data not
shown). The .40% inhibition of the neutrophil influx in the
mast cell lysate experiments demonstrates similar results as
observed by inhibition of ENA-78 in the allergic airway model.
Because TNF has previously been shown to be the major
inducer of ENA-78, in separate experiments preincubation of
the mast cell lysates with anti-TNF did not inhibit the
neutrophil accumulation (data not shown). These latter results
verify that TNF in the mast cell lysates was not inducing the
ENA-78 levels once injected in vivo. Overall, the results
indicate that mast cell-derived ENA-78 may play a major role
in neutrophil accumulation during allergic airway responses.
DISCUSSION
The accumulation of multiple cell populations during allergic
airway responses leads to the tissue damage that facilitates
airway pathology during allergen challenge. In this study, the
examination of a neutrophil-specific chemotactic factor, ENA-
78, has identified that this mast cell-associated C-x-C chemo-
kine is produced early during the allergic airway response. It is
our contention that the early release of ENA-78 by mast cells
contributes to the overall accumulation of neutrophils, but not
eosinophils, during allergic airway inflammation. Our data
indicate that ENA-78 is produced as early as 1–4 h post-
allergen challenge, a time when neutrophils are beginning to
accumulate into the airspace. The passive immunization of
allergic animals with anti-ENA-78 significantly attenuated
(.40% decrease) the accumulation of neutrophils, as assayed
by BAL analysis. It is interesting to note that the in vivo
inhibition of ENA-78 did not affect the eosinophil accumulation.
These latter results follow earlier data indicating that ENA-78 is a
neutrophil-specific chemotactic factor [19, 20]. Although the spe-
cific mouse homolog of ENA-78 has not been isolated (ongoing
studies), the human specific anti-sera does not cross-react with any
other known human or mouse C-x-C chemokines. Thus, we have
designated the molecule in these studies as ENA-78.
One of the earliest cells activated during an allergic response
is the mast cell. In fact, the primary difference between allergic
responses and other types of immune/inflammatory reactions
appears to be mast cell degranulation events. Some of the most
intriguing data on allergic responses indicated that degranu-
lated mast cells release chemotactic factors specific for neutro-
phil and/or eosinophil accumulation [21, 22]. Subsequent
studies have identified nonspecific chemotactic factors, such as
leukotrienes, etc., which are released by mast cells and
contribute to the chemotactic responses. However, mast cells
can also produce multiple chemokines that have the ability to
recruit specific leukocyte populations [23]. Our data indicate
that one of the primary neutrophil chemotactic factors made by
mast cells is ENA-78. ENA-78 was spontaneously released by
MC-9 mast cell lines, and was further enhanced by activating
these cells using IgE 1 antigen, L-NAME (a nitric oxide
synthase inhibitor), and compound 48/80. Inhibition of mast
cell activation in allergic mice with cromolyn sodium also
significantly reduced the production of ENA-78, suggesting
that the mast cell may be an important source of the protein.
When mast cell lysates were injected into the airway of normal
mice, BAL analysis indicated that .80% of the leukocytes that
were found in the airway 4 h post-challenge were neutrophils.
Preincubation of the mast cell supernatants with anti-ENA-78
inhibited .40% of the neutrophil influx. These results were
similar to the data derived within the allergic airway model. It is
interesting to note that when another C-x-C chemokine, MIP-2,
was neutralized in vivo as a specificity control no decrease in
neutrophil accumulation was observed during the allergic
airway response. These results correspond directly to mast cell
data demonstrating that ENA-78 protein was detected from
MC-9 mast cells, but no significant MIP-2 protein was observed
(data not shown). These latter results are quite intriguing
because previous data indicate that macrophage-derived MIP-2
Fig. 6. MC-9 mast cell lysates induce airway neutrophil accumulation that
can be partially blocked by neutralization of ENA-78. Freeze-thaw lysates of
MC-9 cells (1 3 107/mL) were prepared and 30 µL injected intratracheally into
normal mice. Mast cell lysates were preincubated with purified anti-ENA or
control IgG for 30 min and then injected into the trachea. One milliliter BAL
was harvested from the mice 4 h post-injection. Cytospin samples from the BAL
were differentially stained and counted. Control vehicle injections demon-
strated only 10–15% neutrophils in the BAL. Results represent mean 6 SE of
data from at least six mice per group. *P , 0.05 decrease compared to control
ab-treated mice.
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is a primary inducer of neutrophil accumulation during endotox-
emia [24, 25]. Considering that the previous study utilized the
same source of anti-MIP-2 antibody, the results suggest a clear
dichotomy of responses between an acute endotoxin-driven
response and a mast cell-mediated allergic response. Further-
more, macrophages make much greater levels of MIP-2 than
ENA-78, whereas mast cells appear to make much higher levels
of ENA-78 than MIP-2. These latter data further strengthen the
differences between macrophage (endotoxin) and mast cell
(allergic)-mediated inflammatory events.
It is likely that a number of other factors contribute to the
neutrophil accumulation within this model. Nonspecific recruit-
ment factors, such as LTB4, which can be produced early in
allergic responses from mast cells and macrophages [9, 10]
have also been identified in this model as early as 1 h post challenge
[unpublished data]. Other recruitment factors must account for a
considerable amount of the neutrophil accumulation because anti-
ENA-78 inhibited 40–50% of the neutrophil accumulation within
the airway. An interesting aspect of the ENA-78 neutralization
studies indicated that only neutrophils were affected and not
eosinophils, suggesting a true specificity for leukocyte popula-
tions, which follows in vitro chemotaxis data.
The ability of neutrophils to cause damage within tissue upon
degranulation and release of proteases, oxygen radicals, and
other tissue-damaging products, gives these cells the potential
to exert a great deal of damage during an inflammatory
response. Neutrophil-induced damage during allergic pulmo-
nary events, such as in asthma, is relatively controversial.
However, a number of studies have identified the presence of
neutrophils during asthmatic inflammation in patient popula-
tions. In particular, in sudden onset fatal asthma neutrophils
were the predominant cell population found in the airspace
[26]. In an earlier study examining airway reactivity in dogs
exposed to ozone, neutrophils were the predominant cell
population that infiltrated the airways causing airway reactivity
[27]. Supernatants from degranulated neutrophils incubated
with human bronchus increase the responsiveness to histamine,
suggesting that neutrophil-derived products may be linked to
airway hyperreactivity in vivo [5]. Nedocromil sodium, an
anti-inflammatory agent used to control asthmatic inflamma-
tion, blocks neutrophil-induced bronchial hyperresponsiveness
[28]. Altogether, these studies suggest that neutrophil accumu-
lation during allergic airway inflammation may contribute to the
overall tissue damage leading to organ dysfunction.
The identification and preferential production of ENA-78
from mast cell populations may indicate that upon allergic
inflammatory events neutrophil infiltration may be controlled
through the inhibition of mast cell degranulation and release of
ENA-78. These data suggest that one possible target for
particular forms of allergic asthmatic responses may be ENA-78
and neutrophil accumulation.
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